ZLNA ZELLUNA ASA

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026

Oslo, 26 March 2026 - The Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 09:00 CEST on 23 April 2026. 

The General Meeting will be held electronically and all documents related to the Annual General Meeting are available at the Company’s website at 

For further information, please contact:

Anders Tuv, Chairman of the Board

Email:

Phone:

Namir Hassan, Chief Executive Officer

Email:

Phone:

Geir Christian Melen, Chief Financial Officer

Email:

Phone:



 

Attachments



EN
26/03/2026

Underlying

ZLNAZELLUNA ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA – Mandatory notification of trade

Zelluna ASA – Mandatory notification of trade Oslo, Norway, 27 March 2026 - Anders Tuv, Managing Director in Radforsk Invest, and Chairperson and co-founder of Zelluna ASA (Zelluna), has today entered into an agreement with Radforsk Investeringsstiftelse (Radforsk) pursuant to which Mr. Tuv has been granted options (the Options) to acquire up to 200,000 shares held by Radforsk in Zelluna. Each Option provides a right to acquire one share in Zelluna from Radforsk at an exercise price of NOK 18.5 per share (subject to customary adjustments). The Options are immediately vested and may be exer...

March 27, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna to host Capital Markets Update 2026

Zelluna to host Capital Markets Update 2026 Oslo, Norway – 26 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, invites investors, analysts and other stakeholders to attend its Capital Markets Update on 14 April 2026 (11:30–13:00 CET). At the event the company will present progress on its TCR-NK off-the-shelf cell therapy platform and ongoing clinical activities, including perspectives on early clinical data and recent developments in the cell therapy field. The ...

March 26, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026 Oslo, 26 March 2026 - The Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 09:00 CEST on 23 April 2026.  The General Meeting will be held electronically and all documents related to the Annual General Meeting are available at the Company’s website at  For further information, please contact: Anders Tuv, Chairman of the BoardEmail: Phone: Namir Hassan, Chief Executive OfficerEmail: Phone: Geir Christian Melen, Chief Financial OfficerEmail: Phone:   Attachments ...

March 26, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA [ZLNA]: Annual Report 2025

Zelluna ASA [ZLNA]: Annual Report 2025 Oslo, Norway, 25 March 2026 - Zelluna ASA, a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, announces that the Board of Directors of Zelluna ASA has approved the Annual Report for 2025.  A PDF version of the Annual Report, as well as the report in European Single Electronic Format (ESEF), are attached to this release. The Annual Report is also available on the company's website: This information is subject to the disclosure requirements pursuant to Sectio...

March 25, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna announces collaboration with Etcembly for AI-enabled TCR engin...

Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering Oslo, Norway, 09 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a collaboration with Etcembly Ltd, a biotechnology company applying advanced machine learning to T cell receptor (TCR) discovery and engineering. Highlights: AI-enabled collaboration to engineer KKLC1-targeting TCRs for Zelluna's TCR-NK platformBuilds on successful engineering of MAGE-A4 TCR underpinning ...

March 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch